A PHASE 1B STUDY TO ASSESS THE SAFETY, FEASIBILITY, PHARMACOKINETICS, AND ACTIVITY OF PTC299 MONOTHERAPY OR COMBINATION THERAPY WITH HORMONAL AGENTS IN PATIENTS WITH METASTATIC BREAST CANCER.

Trial Profile

A PHASE 1B STUDY TO ASSESS THE SAFETY, FEASIBILITY, PHARMACOKINETICS, AND ACTIVITY OF PTC299 MONOTHERAPY OR COMBINATION THERAPY WITH HORMONAL AGENTS IN PATIENTS WITH METASTATIC BREAST CANCER.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2016

At a glance

  • Drugs Anastrozole; Exemestane; Letrozole; PTC 299
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Apr 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
    • 06 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top